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ENGINEERED CLOSTRIDIUM BOTULINUM Clostridium botulinum . In another embodiment , the payload 
TOXIN ADAPTED TO DELIVER unit may be derived from the payload unit of known toxins 
MOLECULES INTO SELECTED CELLS with modifications . In another embodiment , the payload unit 
may be any proteins that may function as a payload unit for 
RELATED APPLICATION 5 the delivery of the agent . 
In another embodiment , the target cell binding unit may 
This application claims priority to U.S. Provisional Patent contain a specific target cell binding ligand selected from the 
Application No. 62 / 162,582 , filed May 15 , 2015 , which is group consisting of antibody , antibody fragment , affibody , 
incorporated by reference into the present application in its growth factor , a receptor - binding ligand , or combinations 
entirety and for all purposes . 10 thereof . In another embodiment , the target cell binding unit may contain a native or modified binding domain derived 
GOVERNMENT RIGHTS from a heavy chain of C. botulinum toxin other than C2 . 
In another embodiment , the target cell binding unit pref 
This invention was made with government support under erentially binds to a neural cell . In another embodiment , the 
grant number HDTRA - 10 - C - 0055 awarded by Defense 15 composition preferentially delivers the agent to neural cells . 
Threat Reduction Agency of the Department of Defense . In another embodiment , the target cell binding unit is the 
The government has certain rights in the invention . binding domain of the heavy chain of C. botulinum neuro 
toxin C1 ( C1 Hcc ) ( See FIG . 2c , corresponding to amino 
BACKGROUND acids 230-426 of SEQ ID NO : 1 ) . 
In another embodiment , the pore - forming unit may be a 
Clostridium botulinum , a spore - forming , heat - resistant , polypeptide derived from a first type of non - neurotoxic ( i.e. , 
anaerobic bacterium , produces a protein - based toxin ( botu not specifically targeting neuron ) toxin , and the target cell 
linum toxin ) having several serotypes , known as A through binding unit may be a polypeptide derived from a second 
G serotypes , of which serotype C has 3 subtypes , known as type of toxin , wherein the second type is different from the 
serotypes C1 , C2 and C3 . The C1 neurotoxin paralyzes 25 first type of toxin . In another embodiment , the first type of 
people and animals in low doses by blocking acetylcholine non - neurotoxic toxin may be a binary toxin . 
release by neurons , recovery is slow - treatment may require In another embodiment , the pore - forming unit may be a 
ventilation for multiple weeks before a person is able to polypeptide derived from a first Clostridium toxin sub 
breathe again . The C2 toxin is not a neuro - active , and causes serotype , while the target cell binding unit is a polypeptide 
necrosis and hemorrhaging . The C3 toxin is the least char- 30 derived from a second Clostridium toxin sub - serotype , 
acterized of the C sub - serotypes . wherein the second sub - serotype is different from the first 
Most toxin - based delivery systems are multi - domain pro sub - serotype . In another embodiment , the pore - forming unit 
teins that bind target cells and translocate material ( pay is a polypeptide derived from the pore - forming unit of 
loads ) across the lipid bilayer into the cytosol of the targeted Clostridium botulinum toxin C2 ( See FIG . 2c , correspond 
cell . These systems are altered AB - type toxins , consisting of 35 ing to amino acids 1-591 of SEQ ID NO : 2 ) . 
a payload domain ( A ) and a binding / translocation domain In another embodiment , the pore - forming unit may con 
( B ) . The A and B domains can be covalently linked by a tain a native or modified domain derived from a toxin other 
polypeptide or disulfide bond that is later cleaved during the than C. botulinum toxin C2 . In one aspect , the pore - forming 
translocation step . Non - covalently linked ( binary ) A and B unit may contain a native or modified pore - forming domain 
toxin domains are transcribed and translated independently 40 derived from a toxin selected from the group consisting of 
and associate prior to exerting toxicity . The Clostridium Clostridium perfringens alpha- , beta- , epsilon- and iota 
botulinum C2 toxin ( C2 ) is not a neurotoxin , but it has a toxin , Clostridium spiroforme Iota - like toxin , anthrax toxin , 
binary AB toxin design . and combinations thereof . 
In one embodiment , the pore - forming unit is a polypep 
SUMMARY 45 tide derived from the pore - forming unit of Clostridium 
botulinum toxin C2 , while the target cell binding unit may 
The present disclosure advances the art by providing contain a native or modified binding domain derived from a 
chimeric toxin - based delivery compositions ( or systems ) for toxin other than C. botulinum toxin C2 . In one aspect , the 
delivering payload ( or agent ) to a target cell . In one embodi target cell binding unit may contain a native or modified 
ment , the composition may contain a target cell binding unit , 50 binding domain derived from a toxin selected from the 
a pore - forming unit and a payload unit , with or without other group consisting of C. botulinum neurotoxins , Clostridium 
additional components . perfringens toxins alpha , beta , epsilon and iota toxin , 
In one embodiment , the pore - forming unit may be the Clostridium spiroforme lota - like toxin , cholera toxin , 
same as the pore - forming unit of known toxins , for example , anthrax toxin , shiga toxin , shiga - like toxin , diphtheria toxin , 
toxins from Clostridium botulinum . In another embodiment , 55 ricin , exotoxin A , and combinations thereof . 
the pore - forming unit may be derived from the pore - forming In another embodiment , the payload unit is not covalently 
unit of known toxins with modifications . In another embodi bound to the target cell binding unit or the pore - forming unit . 
ment , the pore - forming unit may be any proteins that may In another embodiment , the payload unit is a polypeptide 
function as a pore - forming unit . derived from Clostridium botulinum toxin C2 ( See FIG . 2d , 
The payload unit may contain the agent to be delivered to 60 SEQ ID NO : 3 ) . 
the target cell . In one aspect , the payload unit may bind In another embodiment , the agent comprises at least one 
non - covalently to the pore forming unit , or to the linked pore member selected from the group consisting of a therapeutic 
forming unit and target cell binding unit . In another aspect , agent , a diagnostic agent , an imaging agent , and combina 
the pore forming unit and target cell binding unit are linked tions thereof . In another aspect , the agent may contain at 
covalently . 65 least one member selected from the group consisting of a 
In one embodiment , the payload unit may be the same as toxin , a cell cycle blocker , an apoptosis inducing agent , an 
the payload unit of known toxins , for example , toxins from inhibitor of DNA replication , an inhibitor of RNA synthesis , 
US 10,633,643 B2 
3 4 
an inhibitor of protein synthesis , an enzyme , a protein In another embodiment , a host cell comprising the poly 
binding agent , an antibody , a neutralizing antibody , a label nucleotide is also disclosed . The host cell may be used to 
ing agent , magnetic beads , and combinations thereof . produce the composition for delivering the agent to a target 
In another embodiment , the agent comprises an ADP - ribo cell . In another embodiment , the host cell may be introduced 
syltransferase . In another embodiment , the agent comprises 5 into a subject for delivery of the agent . In another embodi 
C21 from Clostridium botulinum toxin C - 2 . In another ment , for purpose of this disclosure , the host cell may be a 
embodiment , the agent comprises a fluorescent agent for bacterium , or a virus . 
labeling or monitoring the target cell . 
In one embodiment , the target cell may be a cancer cell . BRIEF DESCRIPTION OF THE FIGURES 
In another embodiment , the target cell may be a neuron . In 10 
another embodiment , the target cell may be a cell of a brain FIG . 1 shows ( a ) Molecular steps of intoxication by the 
tumor , a cell of a neuroblastoma , a cell of a retinoblastoma , native C2 toxin ; and ( b ) Model of neural delivery based 
a peripheral neuron , a motor neuron , a sensory neuron , or upon the C211 - C1 and C2It transport system . 
combinations thereof . FIG . 2 shows protein domains of C. botulinum C1 , C. 
In another embodiment , the engineered payload - delivery 15 botulinum C2II , fusion C211 - C1 , and C21 . Numbers corre 
composition may include a target - cell binding unit that is spond to amino acid residues of each protein . ( a ) BONT C1 
covalently bound to a pore - forming unit , and a payload has a linked enzymatic payload domain ( light chain ) and a 
portion adapted with a region capable of non - covalently binding / translocation domain ( heavy chain ) . ( b ) The C2II 
binding to the pore forming unit . In another embodiment , a binding / translocation component has four domains . Amino 
polypeptide ( SEQ ID NO : 4 ) is disclosed which may contain 20 acid residue 182 indicates the trypsin cleavage position for 
the target - cell binding unit covalently bound to the pore activation of C211 into C211a . Domain 4 ( D4 ) was removed 
forming unit linked by a linker , ( EP ) 10 , wherein the target to produce C2IIAD4 as the translocation domain for C2II 
cell binding unit is the binding domain of the heavy chain of C1 . ( c ) The fusion C2II - C1 ( SEQ ID NO : 4 ) was made by 
C. botulinum neurotoxin C1 ( C1 Hcc ) and the pore - forming linking C2IIAD4 ( amino acids 1-591 of SEQ ID NO : 2 ) and 
unit is a polypeptide derived from the pore - forming unit of 25 BONT C1 Hcc ( amino acids 230-426 of SEQ ID NO : 1 ) with 
Clostridium botulinum toxin C2 . an ( EP ) 10 linker flanked by glycine - serine residue pairs on 
In another embodiment , the active payload region is both sides ( SEQ ID NO : 5 ) . Amino acid 182 is the activation 
bound to the pore - forming unit through a coupling region site for C211 - C1 . ( d ) The native C21 enzymatic payload of 
derived from the light - chain payload portion of botulinum the C2 toxin and truncated C2It domain . Amino acids 299 , 
toxin C - 2 . In another aspect , the target - cell binding unit is 30 348 , 387 and 389 are essential for ADP - ribosylation activity 
derived from the target - cell binding unit of botulinum toxin of C21 ( SEQ ID NO : 3 ) and are therefore not present in C2It 
C - 1 . ( SEQ ID NO : 6 ) . 
In another embod the target cell binding unit is the FIG . 3 shows Flow cytometry to evaluate C211 - C1 - me 
binding domain from the heavy chain of C. botulinum diated uptake of C215-488 to differentially GT1b - enriched 
neurotoxin C1 ( C1 Hcc ) , while the pore - forming unit is the 35 cell populations . ( a ) Coomassie stained SDS - PAGE of puri 
pore - forming unit of Clostridium botulinum toxin C - 2 , and fied C2It ( ~ 26 kDa ) . Lanes : M : molecular ruler , 1 : soluble 
the payload unit comprises C21 from Clostridium botulinum elution fraction after thrombin cleavage . ( b ) Indicated N2A 
toxin C - 2 . cells were GT1b - enriched and subsequently incubated with 
In another embodiment , in a composition for delivering recombinant proteins activated C211 - C1 ( 2 ug / mL ) and 
an agent to a target cell comprising a target cell binding unit , 40 C2It - 488 ( 4 ug / mL ) for 2 hours . Cells were then processed 
a pore - forming unit and a payload unit , the target cell with pronase ( 1 ug / mL ) to remove membrane - bound C2It 
binding unit comprises a polypeptide having at least 80 , 90 , 488. Samples were analyzed by a BD FACS Canto II flow 
95 , 99 % , or 100 % sequence identity to the amino acid cytometer using FACSDiva software . ( c ) Quantitative 
sequence 230-426 of SEQ ID NO : 1 , and the pore - forming assessment of intracellular fluorescence by flow cytometry . 
unit comprises a polypeptide having at least 80 , 90 , 95 , 99 % , 45 Percentages are expressed as a mean : SEM ( n = 3 ) and sta 
or 100 % sequence identity to amino acid sequence 1-591 of tistical significance of GT1b - dependent uptake of C21t - 488 
SEQ ID NO : 2 , and the payload unit comprises a polypep mediated by C211 - C1 was calculated using Student's t - test 
tide having at least 80 , 90 , 95 , 99 % , or 100 % sequence by comparison to each control mean value . p < 0.005 . 
identity to amino acid sequence of SEQ ID NO : 3 . FIGS . 4 ( a ) and ( b ) show CLSM images of GT1b differ 
In another embodiment , in a composition for delivering 50 entially GT1b - enriched N2A cells treated with C2II - C1 and 
an agent to a target cell comprising a target cell binding unit , C21-568 . All images were captured with 60x oil lens with 2x 
a pore - forming unit and a payload unit , the target cell optical zoom . N2A populations were treated with a Rab5a 
binding unit and the pore - forming unit are covalently linked GFP early endosome marker ( green ) for 24 hr and stained 
to form a polypeptide having at least 80 , 90 , 95 , 99 % , or with DAPI . Activated C211 - C1 ( 2 ug / mL ) C21t - 568 ( red , 4 
100 % sequence identity to the amino acid sequence of SEQ 55 ug / mL ) and GT1b ( 50 ug / mL ) were incubated for 2 hours . 
ID NO : 4 , and the payload unit comprises a polypeptide ( a ) Cells were enriched with GT1b for 4 hr prior to addition 
having at least 80 , 90 , 95 , 99 % , or 100 % sequence identity of proteins . ( b ) Cells were not GT1b - enriched prior to 
to the amino acid sequence of SEQ ID NO : 3 . addition of proteins . 
In another embodiment , the disclosed composition may FIG . 5 shows Cell rounding of differentially GT1b 
be administered to a subject by injection , wherein the subject 60 enriched cell populations by C21 mediated by C211 - C1 . ( a ) 
contains the target cell ( s ) . Coomassie stained SDS - PAGE of purified C21 . Expected 
In another embodiment , a polynucleotide encoding a masses : C21 - GST ( ~ 75 kDa ) , C21 ( 49 kDa ) molecular ruler , 
polypeptide is disclosed , wherein the polypeptide has at 1 : lysis supernatant , 2 : purification resin prior to thrombin 
least 80 , 90 , 95 , 99 % , or 100 % identity to a polypeptide cleavage , 3 : soluble elution fraction after thrombin cleavage . 
selected from the group consisting of SEQ ID NOs 1-6 . In 65 ( b ) A172 glioblastoma cells were grown to -60 % confluence 
one aspect , the polynucleotide may be carried on a vector . In and enriched as indicated with or without GT1b . ( c ) Flow 
one aspect , the vector may be capable of replicating itself . cytometry of synchronized Hela cells stained with pro 
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pidium iodide with and without release from thymidine natural binding domain of the C2 toxin is located at the 
block over time was used to confirm progression of S phase C - terminal end of the molecule and is designated as D4 ( see 
DNA synthesis after removal of excess thymidine and FIG . 26 ) . In one aspect , D4 is not required for oligomeriza 
addition of deoxycytidine for release . ( d ) Cell rounding of tion because translocation pores can be formed in artificial 
differentially GT1b - enriched synchronized HeLa cells . 5 membranes even when D4 is absent . In another aspect , D4 
is deleted from C2II and replaced with the BoNT C1 binding 
DETAILED DESCRIPTION domain that would target the molecule to peripheral neurons . 
The BoNT C1 Hcc ( FIG . 2a ) preferentially binds ganglio 
Compositions and methods for delivering molecular pay sides GT1b and GD1b . 
loads to the cytosol of target cells are disclosed . Bacteria 10 In another embodiment , BONT / A N - terminal heavy chain 
have evolved mechanisms to target cells and deliver toxic domain ( HCN ) is not included in the chimeric C211 - C1 . It 
payloads to the cytosol of target cells . This mechanism may has been shown that HCN may assist in the orientation of the 
be modified and engineered to deliver beneficial payloads . toxin for association with the membrane by interacting with 
In general , there are two classes of AB - type bacterial phosphatidylinositol phosphates . It is shown that that 
toxins : linked and unlinked ( binary ) . Linked toxins typically 15 although HCN may be active in native BoNT translocation , 
have a single chain protein containing both a toxin domain it is not required in a chimeric C211 - C1 translocation event . 
and a binding / translocation domain . Binary toxins typically In another embodiment , the binding domain is taken from 
have two separately expressed protein molecules , where the a linked toxin and inserted into the binding / translocation 
binding / translocation domain and the toxin domain domain of a binary toxin . This configuration retarget the 
assemble via non - covalent interactions . 20 resulting molecule to neurons while maintaining the C2 
For purpose of this disclosure , the term " derived ” means toxin's mechanism of activation and translocation . It should 
a molecule is constructed based on another molecule and is be noted that a similarity exists between BoNT and C2 
identical , substantially identical or substantially similar in endocytosis and translocation mechanisms in that a clathrin / 
structure to that other molecule . In another aspect , the rho / dynamin - mediated endocytic - endosomal entry pathway 
derived molecule typically performs identical , substantially 25 characterized by pH - dependent protein conformational 
identical or substantially similar functionality as the other changes is implicated for both toxins . 
molecule . In another embodiment , attempts have been made to 
The term sequence identity is used to denote the similarity express a soluble C211 - C1 fusion protein that would oli 
in amino acid or nucleotide sequence . Where a smaller gomerize when activated with trypsin . Direct fusion of the 
molecule is compared to a larger molecule , the smaller 30 C1 Hcc domain was not successful due to solubility prob 
molecule may be compared to the full - length or a partial lems . To remedy this limitation a flexible glycine - serine 
fragment of the larger molecule . linker ( G4S ) , was used but encountered similar issues . 
The native C2 toxin is composed of two separate proteins . Finally , use of a rigid ( EP ) 10 linker resulted in a soluble 
The B domain protein ( C211 ) binds target cells and translo fusion protein that is compatible with activation and oli 
cates the A domain ( C21 , the payload ) . The A domain is an 35 gomerization . SDS - PAGE confirmed that the C211 - C1 
ADP - ribosyltransferase that causes cell rounding and apop fusion protein could be activated by limited trypsin digestion 
tosis initiated by ADP - ribosylation of cytoplasmic actin and then oligomerize . Western blotting is used to confirm 
( FIG . 1a ) . C2II monomers are proteolytically processed to that the C1 Hcc domain is incorporated into the oligomeric 
remove a 20 kDa segment from the N - terminus , which species . BoNT C1 antigenicity specific to the C211 - C1 
activates the binding / translocation domain into C211a . C2IIa 40 oligomer and a decrease in electrophoretic mobility in 
monomers then spontaneously oligomerize and bind the cell comparison to C2IIAD4 demonstrate that C1 Hcc at the 
surface via interactions with asparagine - linked glycans on C - terminus of C211 - C1 does not prevent oligomerization and 
the cell membrane . The A domain , C21 , binds to the C211a is compatible with limited trypsin digestion . 
oligomers and the C211a / C2I complex is internalized by To quantify and visualize binding and internalization of a 
clathrin and Rho - dependent mechanisms . Acidification of 45 payload by C211 - C1 , a fluorescently labeled C - terminally 
the early endosome causes membrane pore formation by truncated C21 - based payload , C2It ( FIG . 2d ) , was con 
C211a oligomers , through which C2I is transported into the structed for use in flow cytometry and microscopy experi 
cytoplasm . ments . C21t that was composed of amino acids 1-226 of C2I 
For therapeutic development , engineering of a binary ( not containing the ADP - ribosylating active site residues ) , 
toxin has certain advantages because the binding / transloca- 50 was fluorescently labeled in two separate versions with 
tion domain and the payload domain may be separately Alexa Fluor 488 ( C2It - 488 ) and 568 ( C2It - 568 ) by amine 
expressed and purified . The C2 toxin from C. botulinum is reactive chemistry . Previously , BoNT C1 Hc entry was 
a binary structure , but is nonspecific as it binds a variety of shown to be GT1b - dependent in N2A cells that were arti 
cells and necessitates N - linked glycans for intoxication ( i.e. , ficially enriched for GT1b30 , and this strategy was adapted 
it is not a specific neurotoxin ) . Disclosed here are methods 55 to study targeting by the C211 - C1 fusion protein . If the 
to engineer the C2 toxin binding domain by retargeting to engineered B component , C211 - C1 , were activated , oli 
neural cells . More specifically , the target binding domain gomerized and associated with the fluorescently labeled A 
from the C1 botulinum neurotoxin may be used . The binding component , C21t , GT1b - dependent uptake of fluorescently 
domain from the C1 botulinum neurotoxin has been previ labeled C2It should be observed . This cellular model does 
ously applied as a targeting component for drug delivery to 60 not employ electrostimulation as previously described to 
peripheral neural tissue in linked toxin designs and as enhance BONT C1 intoxication because entry alone was 
liposomal surface modifications . presumed to be sufficient for the non - neural - specific C2 
In one embodiment , binding domain replacement of the component of the fusion to promote translocation activity . 
C2 toxin requires that the retargeted binding / translocation For flow cytometry , a culture of N2A cells was enriched with 
component retain its ability to oligomerize upon activation , 65 GT1b while another was not , both cultures were incubated 
bind to the new targeting moiety on the cell surface , and with activated C211 - C1 and C2It - 488 , and then both cultures 
translocate the payload into the cytosol of the target cell . The were treated with pronase to remove extracellular proteins 
5 
10 
15 
30 
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prior being analyzed . Cells with intracellular fluorescence EXAMPLES 
above 103 absorbance units were counted by flow cytometry 
and repeated results showed that N2A cell populations Example 1 Construction and Expression of 
enriched with the binding domain receptor GT1b preferen Chimeric Constructs : C211 - C1 , C1 HCC , C2AD4 , 
tially took up C211 - C1 - delivered fluorescent C2It ( FIG . 3 ) . C2It and C21 
The results shown here indicate that the BONT C1 Hcc can 
be used to replace another toxin binding domain and result Plasmid PUC57 - C211 - C1 HCC was purchased as a codon 
in a GT1b - dependent entry specificity . To confirm this optimized gene synthesis product . It consists of the C2II 
uptake is dependent on GT1b and to determine subcellular gene truncated by seven C - terminal amino acids upstream to 
localization within N2A cells , confocal microscopy is the C1 HCC sequence , representing BoNT C1 amino acids 
employed ( FIG . 4 ) . C21-568 preferentially enters GTlb Y1094 - E1291 . Primers C2IIAD4F and C2IIAD4 - GS ( EP ) R 
enriched cells and does not colocalize with fluorescently amplified the gene corresponding to C211 amino acids 
labeled early endosomes . Escape from the early endosome M1 - T592 and added a 5 ' BamHI extension and 3 ' glycine 
by transport of C2It through the pore created by the trans serine- ( EP ) linking region to be used for overlapping PCR 
location domain is a determinant of payload delivery to the with the C1 Hcc domain . The BONT C1 Hcc gene was PCR 
cytosol . These results are consistent with the expected amplified with primers ( EP ) GS - C1 HccF and C1 HccR to 
association between the engineered payload and binding contain a 3 ' EcoRI restriction site . A second round of PCR 
translocation domain by GT1b - specific delivery of C2It by was performed using GS ( EP ) .. GSF and C1 HccR to extend 
C2II - C1 . Lack of colocalization of early endosomes with 20 the 5 ' amplicon of the C1 Hcc to complement the 3 ' of the 
C2It - 568 ( FIG . 4 ( a ) ) provides evidence to pursue other C2IIAD4 - GS ( EP ) sequence . The two resulting fragments 
payloads with the intent of cytosolic delivery to manipulate were fused by overlapping PCR to yield C2IIAD4 - GS 
the cytosome . ( EP ) 10 GS - C1 Hcc ( C2II - C1 ) . To generate C1 HCC , PCR 
To deliver an active enzyme to the cytosol by the C211 - C1 amplification was performed on the pUC57 - C2II - C1 Hcc 
fusion , the native C2 toxin A component , C2I may be 25 template using primers C1 HccF and C1 HCCR . To generate 
produced . The C21 enzyme is known to cause cell rounding C2AD4 , primers C2AD4F and C2AD4R were used to 
in eukaryotic cells by ADP - ribosylation of cytosolic actin . amplify the C211 gene without domain 4. Plasmid PUC57 
The effect of C2I is tested after delivery by C211 - C1 to C2It , was purchased as a codon optimized gene synthesis 
human glioblastoma A172 and HeLa cell lines that are product . C21t ( corresponding to C21 amino acids 1-226 , 
enriched with the ganglioside GT1b . A greater than two - fold PDB 213V ) was directly subcloned into pGex - 2T using 
increase in cell rounding of GT1b - enriched cell populations BamHI and EcoRI restriction sites . Full length C2I ( corre 
is found for both cell lines when compared to controls sponding to C21 amino acids 1-431 ) was generated by 
lacking GT1b enrichment . By comparison , payload - induced overlapping PCR by fusion of C2It to DNA amplified from 
cell rounding of synchronized HeLa cells in the presence of a synthetic DNA using C2IF and C2IR as flanking primers 
the fusion translocator C211 - C1 is less efficient than reported and C210F and C2IOR as overlapping primers . All final 
by Barth et al . in the presence of the native C2II transloca PCR products were digested by BamHI and EcoRI and 
tion domain . A truncated form of C211 - C1 characterized ligated into pGex - 2T . DH5a was transformed by electropo 
during expression may have incorporated into C2II - C1 ration to propagate C211 - C1 , C1 Hcc , C21IAD4 , C2It and 
oligomers , which may result in a decrease in binding effi C21 as N - terminal GST fusions . DNA construct identities 
ciency . Although an apparent lack of monomeric C211 - C1 in were confirmed with sequencing . Primer sequences are 
listed in Table 1 . final purification fractions is evident by SDS - PAGE , it is 
possible that monomeric C211 - C1 dissociated or not incor 
TABLE 1 porated into oligomers compete for binding with the func 
tional form of the oligomeric delivery system . These find- 45 Primer sequences 
ings confirm the native cytosolic activity of the C21 enzyme 
CGCGGATCCATGCTGGTCTCC ( SEQ ID NO : 7 ) specifically delivered by C211 - C1 in a GT1b - dependent 
CCGGCTCTGGTTCCGGTTCAGAACCGGTGATCACTTT 
In another embodiment , alternate payloads based on GACCA GAATATTCATG ( SEQ ID NO : 8 ) 
modified C2It may be used in delivery applications of the ( EP ) GSC1 CCAGAACCAGAGCCAGAACCAGGTTCTACCAACGTTG C2II - C1 fusion protein affecting the natural targets of ?ccF TCAAA GACT ATTGGGG ( SEQ ID NO : 9 ) 
BoNTS ( FIG . 1b ) . A minimal region of amino acid residues 
1-87 in the C21 component is required for complementary ci HCCR CGGGAATTCTTATTCTGAAACCGGGAC ( SEQ ID NO : 10 ) activity with the native C2II translocation domain . Translo 
cation of non - canonical polypeptides may also be possible GS ( EP ) 10GSF AACCGGAACCAGAGCCGGAACCGGAACCGGAACCGG 
with modified C21 , similar to payload development work AGCCA GAACCAGAGCCAGAACC ( SEQ ID NO : 11 ) 
recently conducted with anthrax lethal factor . This disclo ci HCCF CGCGGATCCATGGGCACCAACGTTGTCAAAGACTAT sure provides the basis of exploring other binding specifici TGG ( SEQ ID NO : 12 ) 
ties and payload domains for additional applications . 
CGGGAATTCTTA GGTGATCACTTTGACCAG ( SEQ ID The following examples are provided to illustrate the NO : 13 ) 
present disclosure , but are not intended to be limiting . The 
chemicals and physical parameters are presented as typical CGCGGATCCATGCCGATTATTAAAGAACCGATTGACT 
TCATC AACAAACCGG ( SEQ ID NO : 14 ) reagents or parameters , and various substitutions or modi 
fications may be made in view of this disclosure by one of 65 CCGGAATTCTTAGATTTCTTTGTTTTGGATACCTTCAG 
skills in the art without departing from the principle and CATCA AT ( SEQ ID NO : 15 ) 
spirit of the present invention . 
35 
40 
C2IIAD4F 
manner . C2IIAD4 
GS ( EP ) R 
50 
55 
60 C2IIAD4R 
C2IF 
C2IR 
C2IOF GCAAGAACTGGACTTTTACAACAAAGGCTCGGAAGCCT 
C2IOR CATAGTTTTCCGCACCCCAGGCTTCCGAGCCTTTGTTG 
antibody ( Metabiologics Inc. , Madison , Wis . )? 
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TABLE 1- continued Amine reactive Alexa Fluor dyes were dissolved in anhy 
drous DMSO ( 10 mg / mL ) and stored as aliquots at -20 ° C. 
Primer sequences Purified proteins were concentrated to > 5 mg / mL and 
adjusted to pH 8.5-9.0 with addition of 1 M sodium bicar 
5 bonate . Alexa Fluor in anhydrous DMSO was added to 
GGGG TGCGGAAAACTATG ( SEQ ID NO : 16 ) protein solutions with continuous stiffing for 1 hr at room 
temperature . Excess Alexa Fluor and DMSO was removed 
TAAAA GTCCAGTTCTTGC ( SEQ ID NO : 17 ) by gel filtration ( G - 25 resin ) . Labeled proteins were ultra centrifuged at 80,000xg and subsequently assessed for 
10 degree of labeling by spectrophotometry before and after 
Fusion proteins were overproduced in E. coli BL21 ultracentrifugation . A degree of labeling greater than 1 
( DE3 ) . All cell lines were grown in 400 mL LB , 100 ug / mL fluorescent molecule per molecule of protein was used as a 
ampicillin at 37 ° C. until induction at OD.00 ~ 0.5 with 0.5 quality control cutoff and there was no visible pellet or 
mM IPTG at 25 ° C. for 16 hr . Cells were harvested in 100 appreciable change in spectrophotometric qualities after 
mL aliquots and the pellets were stored at -20 ° C. Cells were 15 ultracentrifugation . 
resuspended in PBS , 1 % Triton , pH 7.4 , and a French press N2A cells were grown in 24 well culture plates to ~ 80 % 
was used to lyse aliquoted cells by three passes at 10,000 psi . confluence . Cells were enriched with GT1b as indicated in 
Cell debris was removed by ultracentrifugation at 80,000xg FIG . 30. Activated C211 - C1 was added at 4 ug / mL and 
for 20 minutes at 4 ° C. Immobilized glutathione agarose C2It - 488 at 2 ug / mL using a 0.5 mL working volume and 
( Genscript ) was used to affinity purify GST fusion protein 20 incubated with cells for 2 hours . Cells were washed twice 
supernatants in batches using 150 uL of washed resin per 15 with PBS , then trypsinized and harvested . Cells were cen 
mL of culture supernatant and an incubation time of 1 hr at trifuged and resuspended in PBS with pronase ( 1 ug / mL ) 
4 ° C. Resin was washed with PBS pH 7.4 to remove and incubated on ice for 5 minutes . Protease inhibitor 
unbound protein . Proteins were cleaved from the GST tag cocktail was then added and cells were centrifuged and 
according to manufacturer's recommendations by bovine 25 resuspended in PBS with inhibitor cocktail . 10,000 events / cells were then counted by BD FACS Canto II flow cytom thrombin and separated from the purification resin by fil eter using a 488 laser line and 530/30 emission band - pass tration using glass wool in a syringe . C2II - C1 was further filter . C2It - 488 positive cells ( greater than the absorbance processed by incubation with trypsin for 30 mins at a 1 : 5 threshold 103 absorbance units ) were counted and evaluated enzyme to substrate ratio concluding with trypsin deactiva 30 as a percentage of total cells . Replicated experiments were 
tion by trypsin inhibitor as described to activate recombinant evaluated by Student's t - test ( n = 3 ) . 
C211 . Collagen - coated 12 mm no . 1 coverslips were placed into 
C211 - C1 , C2IIAD4 , C1 HCC , C21 and C2It were separated 24 - well culture plates and seeded with N2A cells . N2A cells 
by SDS - PAGE using a 10 % polyacrylamide gel or by a were grown to ~ 80 % confluence . Purified C2It was labeled 
4-12 % gradient Bis - Tris Gel . An anti - BONT C1 polyclonal 35 with Alexa Fluor 568 succinimidyl ester ( C2It - 568 ) instead 
of Alexa Fluor 488 to allow for discrimination from the early 
identify C211 - C1 using purified C1 Hcc as a positive control endosome marker . The baculovirus transduction system , 
and C2IIAD4 as a negative control . Proteins were separated BacMam 2.0 Cell Lights Rab5a - GFP early endosomal 
by SDS - PAGE , transferred to a nitrocellulose membrane in marker ( Life Technologies ) , was added ~ 24 hr prior to GT1b 
Towbin buffer , blocked with 5 % powdered milk in PBS- 40 enrichment . Cells were then enriched with GT1b as 
tween buffer and then probed with a 1 : 5,000 dilution of a 1 described in our methods . Recombinant proteins were added 
ug / ul anti - BONT C1 antibody in 0.5 % powdered milk in after washing of cells to remove free gangliosides . Activated 
PBS - tween . Anti - rabbit HRP secondary antibody in 0.5 % C211 - C1 was added at 4 ug / mL and C21t - 568 at 2 ug / mL 
powdered milk , PBS - tween ( 1 : 5,000 ) , was used for signal using a 0.5 mL working volume and incubated with cells for 
detection with ECL blotting substrate . 45 2 hours . Cells were washed with PBS , fixed with 4 % 
Neuro - 2a cells ( N2A ) ( ATCC , CCL - 131 ) were cultured in paraformaldehyde and stained with DAPI . After processing , 
Eagle's minimal essential medium ( EMEM ) supplemented an Olympus Inverted IX - 81 Microscope was used with an 
with 10 % ( v / v ) fetal bovine serum ( FBS ) and penicillin Olympus FV 500 confocal laser scanning microscope in 
streptomycin . A172 cells were grown in DMEM supple sequence mode with laser lines 405 nm ( blue ) , 488 nm 
mented with 10 % ( v / v ) FBS and penicillin - streptomycin 50 ( green ) and 543 nm ( red ) to capture fluorescence images . 
( 100 U / mL - 100 ug / mL ) . HeLa cells ( ATCC , CCL - 2 ) were Corresponding emission barriers used were 430-460 nm , 
cultured in EMEM supplemented with 10 % FBS and peni 505-550 nm and 560-610 nm respectively . Transmitted light 
cillin - streptomycin . Hela cells were synchronized by was used for cell morphology , and all images were captured 
double thymidine block with deoxycytidine release prior to using a 60x oil lens with 2x optical zoom . Contrast of all 
ganglioside enrichment . Ganglioside - enriched cells were 55 images was increased by 20 % . Human glioblastoma A172 
prepared by sonicating 50 ug / mL GT1b ( Enzo Life Sciences , cells ( ATCC , CRL - 1620 ) were grown in 24 well culture 
Farmingdale , N.Y. ) in low - serum ( 0.5 % FBS ) culture plates to -60 % confluence to reduce cell rounding observed 
medium for 20 min at room temperature . Cells were subse at higher confluence . HeLa cells were synchronized as 
quently incubated 4 hr with GT1b . Prior to addition of described in the previous section . Both cell lines were 
recombinant proteins , cells were washed three times with 60 enriched with GT1b as described in our methods at 50 
PBS to remove free ganglioside from the culture medium . ug / mL . C211 - C1 was added at 40 ug / mL and C2I was added 
Flow cytometry with a 488 nm laser line and 586/42 at 20 ug / mL using a 0.5 mL working volume and incubated 
bandpass filter on a BD FACSCanto II was used to confirm with cells for 7 hours . Pictures of cells were taken using an 
HeLa synchronization by staining of DNA with propidium Amscope IN300TC inverted stereo microscope at 40x using 
iodide . 10,000 cells / events were counted and statistical 65 Amscope MT v 3.0.0.5 soft - ware . Rounded cells were 
significance of average fluorescence per cell was determined counted and determined as a percentage of total cells in the 
by Student's t - test ( n = 3 ) . frame . The experiment was replicated three times and evalu 
US 10,633,643 B2 
11 12 
ated for statistical significance with Student's t - test ( n = 3 ) . C2It and activated C2I1 - C1 were incubated with differen 
Institutional biosafety committee approval was obtained tially GT1b - enriched N2A cells . After removal of extracel 
prior to execution of experiments with C21 in a biosafety lular proteins by enzymatic digestion , flow cytometry was 
level 2 laboratory due to anticipated toxicity when combined used to quantitate internalized C2It - 488 . The highest num 
with C2II - C1 . 5 ber of cells with increased fluorescence corresponded to 
GT1b enrichment and addition of C211 - C1 ( FIG . 3b panel 2 ) . Example 2 Retargeting the Clostridium botulinum Background uptake of C2It without C211 - C1 in the presence C2 Toxin to Neuronal Cytosol and absence of GT1b was minimal . Enrichment alone with 
GTlb did not give significantly increased background fluo Multiple recombinant protein constructs were expressed 10 rescence ( FIG . 3b panels 1 , 4 ) . Uptake of the C2It - 488 and purified using E. coli that were based on the BONT 
sub - serotype C1 neurotoxin and the ADP - ribosylating C2 payload alone was also minimal ( FIG . 3b panels 3 , 6 ) . The 
toxin . The native BoNT C1 is depicted in FIG . 2a , and the highest non - target uptake ( ~ 2 % ) occurred in the population 
native C2II binding / translocation domain is depicted in FIG . with C211 - C1 and C2It without GT1b ( FIG . 3b panel 5 ) . 
2b . C2 toxin with C - terminal deletion of domain 4 15 Student's t - test determined that the dependence of C2It - 488 
( C2IIAD4 ) and the C1 neurotoxin binding domain C1 HCC uptake on C211 - C1 and GT1b was significant with p - values 
were produced for use as controls . The C2IIAD4 and Ci < 0.05 between experiments . Overall , an intracellular C2It 
Hcc of BoNT C1 ( 1094-1291 ) were linked with a glutamate 488 delivery efficiency of ~ 18 % ( percentage of cell popu 
proline ten - repeat peptide linker ( EP ) 10 to generate C211 - C1 lation ) was achieved in the presence of GT1b and C211 - C1 
( FIG . 2c ) . In addition , two C21 - based payloads were con- 20 ( FIG . 3c ) . 
structed including a non - toxic C21t ( 1-226 ) that excludes the After quantitation of binding and internalization by flow 
active enzyme site and a full length C21 ( 1-431 ) ( FIG . 2d ) . cytometry , C2It delivered by activated C211 - C1 to targeted 
Cleavage of the glutathione affinity tag ( GST ) and acti cells was visualized by confocal fluorescence light micros vation of C211 - C1 by trypsin into oligomers was confirmed . E. coli BL21 ( DE3 ) cells were lysed and ultracentrifuged to 25 copy to determine intracellular localization . C2It was con 
remove insoluble proteins and the supernatant was passed jugated to an Alexa Fluor 568 fluorescent dye ( C21t - 568 ) . 
over the affinity resin . The resin was then washed exten Channel separated imaging was conducted of C21t - 568 
sively , and protein - bound resin was loaded to examine the ( red ) , Rab5a - GFP early endosomal marker ( green ) , and 
mass of the full length resin - bound protein and the extent of DAPI nuclei ( blue ) . It was observed that an intracellular thrombin cleavage . The resin was then treated with thrombin 30 C2II - C1 - delivered C2It - 568 colocalized at a low level with to cleave the GST tag . Proteins were then eluted from the 
resin and treated with trypsin . The trypsin - activated C2II - C1 early endosomes when cells were enriched with GT1b ( FIG . 
monomers oligomerized as indicated by a shift in electro 4 ( a ) ) . This result was consistent with endosomal escape of 
phoretic migration from an observed mass of -90 kDa to a C2It by an active translocation domain . Without GT1b , 
much greater mass than 250 kDa . Activated C2IIAD4 was 35 C2It - 568 signals were confined generally to the outside of also produced with the same method and compared to 
activated C211 - C1 . The heptameric form of C211 - C1 had an the cell with low levels of reporter associated with early 
expected molecular mass of -497 kDa , and heptameric endosomes ( FIG . 4 ( b ) ) . These findings are consistent with 
C2AD4 had as an expected molecular mass of ~ 350 kDa . the binding / internalization flow cytometry data ( FIG . 3b , c ) . 
The C211 - C1 oligomer had a higher mass than that of 40 Additional control permutations lacking C211 - C1 , GT1b or 
C2IIAD4 oligomer , as expected . The oligomerized forms of C2It - 568 did not achieve intracellular delivery of C21t C211 - C1 and C2AD4 maintained stability in SDS during 
electrophoresis and dissociated partially with the addition of reporters with early endosomal dissociation . 
heating . An additional band was identified during purifica Retargeting of the Native C21 Enzyme by C211 - C1 . 
tion with anti - BONT C1 antigenicity . However , after exten- 45 Delivery of an active enzyme to the cytosol was deter 
sive heating of C211 - C1 oligomers , it was determined the mined by cell rounding caused by native C21 payload in both 
dissociated composition was predominantly of full - length human glioblastoma A172 and synchronized HeLa cell lines 
C2II - C1 monomers . differentially enriched with GT1b . Full length C2I was Western blotting was conducted of oligomerized C211 - C1 
and C2IIAD4 Proteins were then probed with an anti - BONT 50 purified ( FIG . 5a ) , combined with activated C211 - C1 , and 
C1 antibody . BoNT C1 HCC ( MW ~ 23 kDa ) was used as a then added to cell line cultures for seven hours . Cell round 
positive control . C211 - C1 oligomers cross - reacted with the ing was determined to be 2.8 - fold higher than the non - GT1b 
anti - BONT C1 antibody , while the oligomerized C2IIAD4 enriched A172 cell population ( FIG . 5b ) . Delivery - depen 
did not cross - react . This confirmed that BONT C1 HCC was dent cell rounding of synchronized HeLa cells was investi successfully fused to C2IIAD4 via the ( EP ) 10 repeat linker 55 
in the oligomeric state . gated as a non - neural cell line enriched with GT1b for a 
Neural Targeting of Fluorescently Labeled C2It Payloads comparison to previous data of the wild type C211 without 
by C211 - C1 . GT1b enrichment previously reported by Barth et al . Infect . 
The binding and payload internalization that were medi Immun . 67 , 5083-5090 ( 1999 ) . Flow cytometry methods 
ated by the C211 - C1 binding / translocation component was 60 confirmed the synchronization of HeLa cells in the early 
investigated using a fluorescently labeled C21 - based pay S - phase by quantitation of DNA ( FIG . 5c ) . In synchronized 
load , C2It ( FIG . 2d ) , to populations of cells with and without HeLa cells , rounding was 2.1 - fold above the non - GT1b the GT1b ganglioside receptor . Murine neuroblastoma 
Neuro - 2A ( N2A ) cells do not naturally present GT1b on the enriched population . ( FIG . 5d ) . Student's t - test was used to 
cell surface , but can be artificially enriched . After payload 65 evaluate the experimental significance between experi 
C2It was purified ( FIG . 3a ) , an Alexa Fluor 488 succinim ments . Comparing control populations to the GT1b - enriched 
idyl ester label was conjugated to the protein ( C21t - 488 ) . population produced p - values < 0.05 . 
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List of Sequences of SEQ ID NOs 1-6 : - continued 
List of sequences of SEQ ID NOS 1-6 : 
List of sequences of SEQ ID NOS 1-6 : 
SEVLLKPNYSNTNEKSKFIPNNTLFSNAKLKANANRDTDRDGIPDEWEIN 
5 
SEQ ID NO : 1 - 
NNINDSKILSLQNRKNTLVDTSGYNAEVSEEGDVQLNPIFPFDFKLGSSG GYTVMNQKAVAWDDKFAANGYKKYVSNPFKPCTANDPYTDFEKVSGQIDP 
EDRGKVIVTONENIVYNSMYESFSISFWIRINKWVSNLPGYTIIDSVKNN SVSMVARDPMISAYPIVGVQMERLVVSKSETITGDSTKSMS KSTSHSSTN 
SGWSIGIISNFLVFTLKQNEDSEQSINFSYDISNNAPGYNKWFFVTVTNN INTVGAEVSGSLQLAGGIFPVFSMSASANYSHTWQNTSTVDDTTGESFSQ 
10 
MMGNMKIYINGKLIDTIKVKELTGINFSKTITFEINKIPDTGLITSDSDN GLSINTAESAYINPNIRYYNTGTAPVYNVTPTTTIVIDKQSVATIKGQES 
INMWIRDFYIFAKELDGKDINILFNSLQYTNVVKDYWGNDLRYNKEYYMV LIGDYLNPGGTYPIIGEPPMALNTMDQFSSRLIPINYNQLKSIDNGGTVM 
NIDYLNRYMYANSRQIVFNTRRNNNDFNEGYKITIKRIRGNTNDTRVRGG LSTSQFTGNFAKYNSNGNLVTDGNNWGPYLGTIKSTTASLTLSLPDOTTO 
15 
DILYFDMTINNKAYNLFMKNETMYADNHSTEDIYAIGLREQTKDINDNII VAVVAPNFSDPEDKTPRLTLEQALVKAFRLEKKNGKFYFHGMEISANOKI 
FQIQPMNNTYYYASQIFKSNFNGENISGICSIGTYRFRLGGDWYRHNYLV QVFLDRNTNVDFENQLKNTANKDIMNCIIKRNMNILVKVITGSEPEPEPE 
PTVKQGNYASLLESTSTHWGFVPVSE PEPEPEPEPEPEPGSTNVVKDYWGNDLRYNKEYYMVNIDYLNRYMYANSR 
20 
QIVFNTRRNNNDFNEGYKIIIKRIRGNTNDTRVRGGDILYFDMTINNKAY SEQ ID NO : 2 
MLVSKFENSVKNSNKNYFTINGLMGYYFENDFFNLNIISPTLDGNLTFSK 
NLFMKNETMYADNHSTEDIYAIGLREQTKDINDNIIFQIQPMNNTYYYAS 
EDINSILGNKIIKSARWIGLIKPSITGEYILS TNSPNCRVELNGEIFNLS 
QIFKSNFNGENISGICSIGTYRFRLGGDWYRHNYLVPTVKQGNYASLLES 
LNTSNTVNLIQGNVYDIRIEQLMSENQLLKNYEGIKLYWETSDIIKEIIP 25 TS THWGFVPVSE 
SEVLLKPNYSNTNEKSKFIPNNTLFSNAKLKANANRDTDRDGIPDEWEIN 
SEQ ID NO : 5 
GSEPEPEPEPEPEPEPEPEPEPGS GYTVMNOKAVAWDDKFAANGYKKYVSNPFKPCTANDPYTDFEKVSGQIDP 
SVSMVARDPMISAYPIVGVOMERLVVSKSETITGDSTKSMSKSTSHSSTN SEQ ID NO : 6 
30 MPIIKEPIDFINKPESEAKEWGKEEEKRWFTKLNNLEEVAVNQLKNKEYK 
INTVGAEVSGSLQLAGGIFPVFSMSASANYSHTWQNTSTVDDTTGESFSQ 
TKIDNFSTDILFSSLTAIEIMKEDENONLFDVERIREALLKNTLDRDAIG 
GLSINTAESAYINPNIRYYNTGTAPVYNVTPTTTIVIDKQSVATIKGQES 
YVNFTPKELGINFSIRDVELDRDISDETLDKVRQQI INQEYTKFSFISLG 
LIGDYLNPGGTYPIIGEPPMALNTMDQFSSRLIPINYNQLKSIDNGGTVM 
35 LNDNSINESVPVIVKTRVPTTFDYGVLNDKETVSLLLNQGFSIIPESAII 
LSTSQFTGNFAKYNSNGNLVTDGNNWGPYLGTIKSTTASLTLSLPDQTTQ 
TTIKGKDYILIEGSLSQELDFYNKG 
VAVVAPNFSDPEDKTPRLTLEQALVKAFRLEKKNGKFYFHGMEISANOKI 
QVFLDRNTNVDFENQLKNTANKDIMNCIIKRNMNILVKVITFKENISSIN 
IIND TNFGVESMTGLSKRI KGNDGIYRASTKSFSFKSKEI KYPEGFYRMR 
FVIQSYEPFTCNFKLFNNLIYSNSFDIGYYDEFFYFYCNGSKSFFDISCD 
While the disclosure has been particularly shown and 
40 described with reference to particular embodiments thereof , 
it will be understood by those skilled in the art that various 
other changes in the form and details may be made without 
departing from the spirit and scope of the disclosure . It is to 
be understood that various changes may be made in adapting 
45 the invention to different embodiments without departing 
from the inventive concepts disclosed herein and compre 
hended by the claims that follow . 
IINSINRLSGVFLI 
SEQ ID NO : 3 
MPIIKEPIDFINKPESEAKEWGKEEEKRWFTKLNNLEEVAVNQLKNKEYK 
TKIDNFSTDILFSSLTAIEIMKEDENONLFDVERIREALLKNTLDRDAIG 
YVNFTPKELGINFSIRDVELDRDISDETLDKVRQQI INQEYTKFSFISLG REFERENCES 
50 
LNDNSINESVPVIVKTRVPTTFDYGVLNDKETVSLLLNQGFSIIPESAII 
TTIKGKDYILIEGSLSQELDFYNKGSEAWGAENYGDYISKLSHEQLGALE 
GYLHSDYKAINSYLRNNRVPNNDELNKKIELISSALSVKPIPOTLIAYRR 
55 
VDGIPFDLPSDFSFDKKENGEIIADKQKLNEFIDKWTGKEIENLSFSSTS 
LKSTPSSFSKSRFIFRLRLSEGAIGAFIYGFSGFQDEQEILLNKNSTFKI 
FRITPITSIINRVTKMTQVVIDAEGIQNKEI 
The contents of all cited references ( including literature 
references , patents , patent applications , and websites ) that 
may be cited throughout this application or listed below are 
hereby expressly incorporated by reference in their entirety 
for any purpose into the present disclosure . The disclosure 
may employ , unless otherwise indicated , conventional tech 
niques of immunology , molecular biology and cell biology , 
which are well known in the art . 
The present disclosure also incorporates by reference in 
their entirety techniques and methods well known in the 
field of molecular biology . These techniques include , but are 
not limited to , techniques described in the following publi 
cations . 
65 1. Schiavo , G. , Matteoli , M. & Montecucco , C. Neurotoxins 
affecting neuroexocytosis . Physiol . Rev. 80 , 717-766 
( 2000 ) . 
60 
SEQ ID NO : 4 - 
MLVSKFENSVKNSNKNYFTINGLMGYYFENDFFNLNIISPTLDGNLTFSK 
EDINSILGNKIIKSARWIGLIKPSITGEYILSTNSPNCRVELNGEIFNLS 
LNTSNTVNLIQGNVYDIRIEQLMSENQLLKNYEGIKLYWETSDIIKEIIP 
10 
15 
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2. Singh , B. R. et al . Clostridial neurotoxins as a drug 22. Haug , G. et al . Cellular uptake of Clostridium botulinum 
delivery vehicle targeting nervous system . Biochimie 92 , C2 toxin : Membrane translocation of a fusion toxin 
1252-1259 ( 2010 ) . requires unfolding of its dihydro folate reductase domain . 
3. Vazquez - Cintron , E. J. et al . Atoxic derivative of botuli Biochemistry 42 , 15284-15291 ( 2003 ) . 
num neurotoxin A as a prototype molecular vehicle for 5 23. Chaddock , J. A. et al . Inhibition of vesicular secretion in 
targeted delivery to the neuronal cytoplasm . PLoS ONE 9 , both neuronal and nonneuronal cells by a retargeted 
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10.1186 / 1471-2210-9-12 ( 2009 ) . Clostridium botulinum C2 toxin is essential for receptor 
5. Ho , M. F. et al . Recombinant botulinum neurotoxin A binding . Infect . Immun . 68 , 4566-4573 ( 2000 ) . 
heavy chain - based delivery vehicles for neuronal cell 25. Gill , D. M. Bacterial toxins - a table of lethal amounts . 
targeting . Protein Eng . Des . Sel . 24 , 247-253 ( 2011 ) . Microbiol . Rev. 46 , 86-94 ( 1982 ) . 
6. Webb , R. P. , Smith , T. J. , Wright , P. , Brown , J. & Smith , 26. Montecucco , C. & Schiavo , G. Mechanism of action of 
L. A. Production of catalytically inactive BONT / A1 holo tetanus and botulinum neurotoxins . Mol . Microbiol . 13 , 
protein and comparison with BONT / A1 subunit vaccines 1-8 ( 1994 ) . 
against toxin subtypes A1 , A2 , and A3 . Vaccine 27 , 27. Strotmeier , J. et al . The biological activity of botulinum 
4490-4497 ( 2009 ) . neurotoxin type C is dependent upon novel types of 
7. Mechaly , A. , McCluskey , A. J. & Collier , R. J. Changing 20 ganglioside binding sites . Mol . Microbiol . 81 , 143-156 
the receptor specificity of anthrax toxin . mBio 3 , 00088 ( 2011 ) . 
00012 , doi : 10.1128 / mBio.00088-12 ( 2012 ) . 28. Simpson , L. L. The origin , structure , and pharmacologi 
8. Fahrer , J. et al . C2 - streptavidin mediates the delivery of cal activity of botulinum toxin . Pharmacol . Rev. 33 , 
biotin - conjugated tumor suppressor protein P53 into 155-188 ( 1981 ) . 
tumor cells . Bioconjug . Chem . 24 , 595-603 ( 2013 ) . 25 29. Yowler , B.C. & Schengrund , C. L. Glycosphingolipids 
9. Fahrer , J. , Rieger , J. , van Zandbergen , G. & Barth , H. The Sweets for botulinum neurotoxin . Glycoconj . J. 21 , 287 
C2 - streptavidin delivery system promotes the uptake of 293 ( 2004 ) . 
biotinylated molecules in macrophages and T - leukemia 30. Karalewitz , A. P. A. , Fu , Z. J. , Baldwin , M. R. , Kim , J. 
cells . Biol . Chem . 391 , 1315-1325 ( 2010 ) . J. P. & Barbieri , J. T. Botulinum neurotoxin serotype C 
10. Fahrer , J. et al . Genetically engineered clostridial C2 30 associates with dual ganglioside receptors to facilitate cell 
toxin as a novel delivery system for living mammalian entry . J. Biol . Chem . 287 , 40806-40816 ( 2012 ) . 
cells . Bioconjug . Chem . 21 , 130-139 ( 2010 ) . 31. Barth , H. , Klingler , M. , Aktories , K. & Kinzel , V. 
11. Schleberger , C. , Hochmann , H. , arth , H. , Aktories , K. Clostridium botulinum C2 toxin delays entry into mitosis 
& Schulz , G. E. Structure and action of the binary C2 and activation of p34 ( cdc2 ) kinase and cdc25 - C phos 
toxin from Clostridium botulinum . J. Mol . Biol . 364 , 35 phatase in HeLa cells . Infect . Immun . 67 , 5083-5090 
705-715 ( 2006 ) . ( 1999 ) . 
12. Aktories , K. et al . Botulinum - C2 toxin ADP - ribosylates 32. Varkouhi , A. K. , Scholte , M. , Storm , G. & Haisma , H. J. 
actin . Nature 322 , 390-392 ( 1986 ) . Endosomal escape pathways for delivery of biologicals . J. 
13. Simpson , L. L. Molecular basis for the pharmacological Control . Release 151 , 220-228 ( 2011 ) . 
actions of Clostridium botulinum type C2 toxin . J. Phar- 40 33. Sandvig , K. & van Deurs , B. Delivery into cells : lessons 
macol . Exp . Ther . 230 , 665-669 ( 1984 ) . learned from plant and bacterial toxins . Gene Ther . 12 , 
14. Ohishi , I. , Iwasaki , M. & Sakaguchi , G. Purification and 865-872 ( 2005 ) . 
characterization of 2 components of botulinum C2 toxin . 34. Verdurmen , W. P. , Luginbuhl , M. , Honegger , A. & 
Infect . Immun 30 , 668-673 ( 1980 ) . Pluckthun , A. Efficient cell - specific uptake of binding 
15. Iwasaki , M. , Ohishi , I. & Sakaguchi , G. Evidence that 45 proteins into the cytoplasm through engineered modular 
botulinum C2 - toxin has 2 dissimilar components . Infect . transport systems . J. Control . Release 200 , 13-22 ( 2015 ) . 
Immun 29 , 390-394 ( 1980 ) . 35. Eckhardt , M. , Barth , H. , Blocker , D. & Aktories , K. 
16. Ohishi , I. Activation of botulinum C2 toxin by trypsin . Binding of Clostridium botulinum C2 toxin to asparagine 
Infect . Immun . 55 , 1461-1465 ( 1987 ) . linked complex and hybrid carbohydrates . J. Biol . Chem . 
17. Nagahama , M. et al . Binding and Internalization of 50 275 , 2328-2334 ( 2000 ) . 
Clostridium botulinum C2 Toxin . Infect . Immun 77,5139 36. Andreu , A. , Fairweather , N. & Miller , A. D. Clostridium 
5148 ( 2009 ) . neurotoxin fragments as potential targeting moieties for 
18. Fritz , G. , Schroeder , P. & Aktories , K. Isolation and liposomal gene delivery to the CNS . Chem Bio Chem 9 , 
characterization of a Clostridium botulinum C2 toxin 219-231 ( 2008 ) . 
resistant cell line : evidence for possible involvement of 55 37. Edupuganti , O. P. et al . Targeted delivery into motor 
the cellular C211 receptor in growth - regulation . Infect . nerve terminals of inhibitors for SNARE - cleaving pro 
Immun 63 , 2334-2340 ( 1995 ) . teases via liposomes coupled to an atoxic botulinum 
19. Pust , S. , Barth , H. & Sandvig , K. Clostridium botulinum neurotoxin . FEBS J. 279 , 2555-2567 ( 2012 ) . 
C2 toxin is internalized by clathrin- and Rho - dependent 38. Tsukamoto , K. et al . Binding of Clostridium botulinum 
mechanisms . Cell Microbiol . 12 , 1809-1820 ( 2010 ) . type C and D neurotoxins to ganglioside and phospho 
20. Kaiser , E. , Haug , G. , Hliscs , M. ,Aktories , K. & Barth , lipid - Novel insights into the receptor for clostridial neu 
H. Formation of a biologically active toxin complex of the rotoxins . J. Biol . Chem . 280 , 35164-35171 ( 2005 ) . 
binary Clostridium botulinum C2 toxin without cell mem 39. Rummel , A. et al . Botulinum neurotoxins C , E and F 
brane interaction . Biochemistry 45 , 13361-13368 ( 2006 ) . bind gangliosides via a conserved binding site prior to 
21. Barth , H. et al . Cellular uptake of Clostridium botulinum 65 stimulation - dependent uptake with botulinum neurotoxin 
C2 toxin requires oligomerization and acidification . J. F utilising the three isoforms of SV2 as second receptor . 
Biol . Chem . 275 , 18704-18711 ( 2000 ) . J. Neurochem . 110 , 1942-1954 ( 2009 ) . 
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SEQUENCE LISTING 
< 160 > NUMBER OF SEQ ID NOS : 14 
< 210 > SEQ ID NO 1 
< 211 > LENGTH : 426 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Clostridium botulinum 
< 400 > SEQUENCE : 1 
Asn Asn Ile Asn Asp Ser Lys Ile Leu Ser Leu Gln Asn Arg Lys Asn 
1 5 10 15 
Thr Leu Val Asp Thr Ser Gly Tyr Asn Ala Glu Val Ser Glu Glu Gly 
20 25 30 
Asp Val Gin Leu Asn Pro Ile Phe Pro Phe Asp Phe Lys Leu Gly Ser 
35 40 45 
Ser Gly Glu Asp Arg Gly Lys Val Ile Val Thr Gln Asn Glu Asn Ile 
50 55 60 
Val Tyr Asn Ser Met Tyr Glu Ser Phe Ser Ile Ser Phe Trp Ile Arg 
65 70 75 80 
Ile Asn Lys Trp Val Ser Asn Leu Pro Gly Tyr Thr Ile Ile Asp Ser 
85 90 95 
Val Lys Asn Asn Ser Gly Trp Ser Ile Gly Ile Ile Ser Asn Phe Leu 
100 105 110 
Val Phe Thr Leu Lys Gin Asn Glu Asp Ser Glu Gin Ser Ile Asn Phe 
115 120 125 
Ser Tyr Asp Ile Ser Asn Asn Ala Pro Gly Tyr Asn Lys Trp Phe Phe 
US 10,633,643 B2 
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- continued 
130 135 140 
Val Thr Val Thr Asn Asn Met Met Gly Asn Met Lys Ile Tyr Ile Asn 
145 150 155 160 
Gly Lys Leu Ile Asp Thr Ile Lys Val Lys Glu Leu Thr Gly Ile Asn 
165 170 175 
Phe Ser Lys Thr Ile Thr Phe Glu Ile Asn Lys Ile Pro Asp Thr Gly 
180 185 190 
Leu Ile Thr Ser Asp Ser Asp Asn Ile Asn Met Trp Ile Arg Asp Phe 
195 200 205 
Tyr Ile Phe Ala Lys Glu Leu Asp Gly Lys Asp Ile Asn Ile Leu Phe 
210 215 220 
Asn Ser Leu Gin Tyr Thr Asn Val Val Lys Asp Tyr Trp Gly Asn Asp 
225 230 235 240 
Leu Arg Tyr Asn Lys Glu Tyr Tyr Met Val Asn Ile Asp Tyr Leu Asn 
245 250 255 
Arg Tyr Met Tyr Ala Asn Ser Arg Gin Ile Val Phe Asn Thr Arg Arg 
260 265 270 
Asn Asn Asn Asp Phe Asn Glu Gly Tyr Lys Ile Ile Ile Lys Arg Ile 
275 280 285 
Arg Gly Asn Thr Asn Asp Thr Arg Val Arg Gly Gly Asp Ile Leu Tyr 
290 295 300 
Phe Asp Met Thr Ile Asn Asn Lys Ala Tyr Asn Leu Phe Met Lys Asn 
305 310 315 320 
Glu Thr Met Tyr Ala Asp Asn His Ser Thr Glu Asp Ile Tyr Ala Ile 
325 330 335 
Gly Leu Arg Glu Gin Thr Lys Asp Ile Asn Asp Asn Ile Ile Phe Gin 
340 345 350 
Ile Gin Pro Met Asn Asn Thr Tyr Tyr Tyr Ala Ser Gin Ile Phe Lys 
355 360 365 
Ser Asn Phe Asn Gly Glu Asn Ile Ser Gly Ile Cys Ser Ile Gly Thr 
370 375 380 
Tyr Arg Phe Arg Leu Gly Gly Asp Trp Tyr Arg His Asn Tyr Leu Val 
385 390 395 400 
Pro Thr Val Lys Gin Gly 
405 
Asn Tyr Ala Ser Leu Le 
410 
Glu Ser Thr Ser 
415 
Thr His Trp Gly Phe Val Pro Val Ser Glu 
420 425 
< 210 > SEQ ID NO 2 
< 211 > LENGTH : 714 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Clostridium botulinum 
< 400 > SEQUENCE : 2 
Met Leu Val Ser Lys Phe Glu Asn Ser Val Lys Asn Ser Asn Lys Asn 
1 5 10 15 
Tyr Phe Thr Ile Asn Gly Leu Met Gly Tyr Tyr Phe Glu Asn Asp Phe 
20 25 30 
Phe Asn Leu Asn Ile Ile Ser Pro Thr Leu Asp Gly Asn Leu Thr Phe 
35 40 45 
Ser Lys Glu Asp Ile Asn Ser Ile Leu Gly Asn Lys Ile Ile Lys Ser 
50 55 60 
Ala Arg Trp Ile Gly Leu Ile Lys Pro Ser Ile Thr Gly Glu Tyr Ile 
65 70 75 80 
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- continued 
Leu Ser Thr Asn Ser Pro Asn Cys Arg Val Glu Leu Asn Gly Glu Ile 
85 90 95 
Phe Asn Leu Ser Leu Asn Thr Ser Asn Thr Val Asn Leu Ile Gin Gly 
100 105 110 
Asn Val Tyr Asp Ile Arg Ile Glu Gln Leu Met Ser Glu Asn Gin Leu 
115 120 125 
Leu Lys Asn Tyr Glu Gly Ile Lys Leu Tyr Trp Glu Thr Ser Asp Ile 
130 135 140 
Ile Lys Glu Ile Ile Pro Ser Glu Val Leu Leu Lys Pro Asn Tyr Ser 
145 150 155 160 
Asn Thr Asn Glu Lys Ser Lys Phe Ile Pro Asn Asn Thr Leu Phe Ser 
165 170 175 
Asn Ala Lys Leu Lys Ala Asn Ala Asn Arg Asp Thr Asp Arg Asp Gly 
180 185 190 
Ile Pro Asp Glu Trp Glu Ile Asn Gly Tyr Thr Val Met Asn Gln Lys 
195 200 205 
Ala Val Ala Trp Asp Asp Lys Phe Ala Ala Asn Gly Tyr Lys Lys Tyr 
210 215 220 
Val Ser Asn Pro Phe Lys Pro Cys Thr Ala Asn Asp Pro Tyr Thr Asp 
225 230 235 240 
Phe Glu Lys Val Ser Gly Gin Ile Asp Pro Ser Val Ser Met Val Ala 
245 250 255 
Arg Asp Pro Met Ile Ser Ala Tyr Pro Ile Val Gly Val Gin Met Glu 
260 265 270 
Arg Leu Val Val Ser Lys Ser Glu Thr Ile Thr Gly Asp Ser Thr Lys 
275 280 285 
Ser Met Ser Lys Ser Thr Ser His Ser Ser Thr Asn Ile Asn Thr Val 
290 295 300 
Gly Ala Glu Val Ser Gly Ser Leu Gln Leu Ala Gly Gly Ile Phe Pro 
305 310 315 320 
Val Phe Ser Met Ser Ala Ser Ala Asn Tyr Ser His Thr Trp Gin Asn 
325 330 335 
Thr Ser Thr Val Asp Asp Thr Thr Gly Glu Ser Phe Ser Gin Gly Leu 
340 345 350 
Ser Ile Asn Thr Ala Glu Ser Ala Tyr Ile Asn Pro Asn Ile Arg Tyr 
355 360 365 
Tyr Asn Thr Gly Thr Ala Pro Val Tyr Asn Val Thr Pro Thr Thr Thr 
370 375 380 
Ile Val Ile Asp Lys Gin Ser Val Ala Thr Ile Lys Gly Gln Glu Ser 
385 390 395 400 
Leu Ile Gly Asp Tyr Leu Asn Pro Gly Gly Thr Tyr Pro Ile Ile Gly 
405 410 415 
Glu Pro Pro Met Ala Leu Asn Thr Met Asp Gln Phe Ser Ser Arg Leu 
420 425 430 
Ile Pro Ile Asn Tyr Asn Gin Leu Lys Ser Ile Asp Asn Gly Gly Thr 
435 440 445 
Val Met Leu Ser Thr Ser Gin Phe Thr Gly Asn Phe Ala Lys Tyr Asn 
450 455 460 
Ser Asn Gly Asn Leu Val Thr Asp Gly Asn Asn Trp Gly Pro Tyr Leu 
465 470 475 480 
Gly Thr Ile Lys Ser Thr Thr Ala Ser Leu Thr Leu Ser Leu Pro Asp 
485 490 495 
Gin Thr Thr Gin Val Ala Val Val Ala Pro Asn Phe Ser Asp Pro Glu 
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500 505 510 
Asp Lys Thr Pro Arg Leu Thr Leu Glu Gin Ala Leu Val Lys Ala Phe 
515 520 525 
Arg Leu Glu Lys Lys Asn Gly Lys Phe Tyr Phe His Gly Met Glu Ile 
530 535 540 
Ser Ala Asn Gin Lys Ile Gin Val Phe Leu Asp Arg Asn Thr Asn Val 
555 560 545 550 
Asp Phe Glu Asn Gin Leu Lys Asn Thr Ala Asn Lys Asp Ile Met Asn 
565 570 575 
Cys Ile Ile Lys Arg Asn Met Asn Ile Leu Val Lys Val Ile Thr Phe 
580 585 590 
Lys Glu Asn Ile Ser Ser Ile Asn Ile Ile Asn Asp Thr Asn Phe Gly 
595 600 605 
Val Glu Ser Met Thr Gly Leu Ser Lys Arg Ile Lys Gly Asn Asp Gly 
610 615 620 
Ile Tyr Arg Ala Ser Thr Lys Ser Phe Ser Phe Lys Ser Lys Glu Ile 
625 630 635 640 
Lys Tyr Pro Glu Gly Phe Tyr Arg Met Arg Phe Val Ile Gin Ser Tyr 
645 650 655 
Glu Pro Phe Thr Cys Asn Phe Lys Leu Phe Asn Asn Leu Ile Tyr Ser 
660 665 670 
Asn Ser Phe Asp Ile Gly Tyr Tyr Asp Glu Phe Phe Tyr Phe Tyr Cys 
675 680 685 
Asn Gly Ser Lys Ser Phe Phe Asp Ile Ser Cys Asp Ile Ile Asn Ser 
690 695 700 
Ile Asn Arg Leu Ser Gly Val Phe Leu Ile 
705 710 
< 210 > SEQ ID NO 3 
< 211 > LENGTH : 431 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Clostridium botulinum 
< 400 > SEQUENCE : 3 
Met Pro Ile Ile Lys Glu Pro Ile Asp Phe Ile Asn Lys Pro Glu Ser 
1 5 10 15 
Glu Ala Lys Glu Trp Gly Lys Glu Glu Glu Lys Arg Trp Phe Thr Lys 
20 25 30 
Leu Asn Asn Leu Glu Glu Val Ala Val Asn Gin Leu Lys Asn Lys Glu 
35 40 45 
Tyr Lys Thr Lys Ile Asp Asn Phe Ser Thr Asp Ile Leu Phe Ser Ser 
50 55 60 
Leu Thr Ala Ile Glu Ile Met Lys Glu Asp Glu Asn Gin Asn Leu Phe 
65 70 75 80 
Asp Val Glu Arg Ile Arg Glu Ala Leu Leu Lys Asn Thr Leu Asp Arg 
85 90 95 
Asp Ala Ile Gly Tyr Val Asn Phe Thr Pro Lys Glu Leu Gly Ile Asn 
100 105 110 
Phe Ser Ile Arg Asp Val Glu Leu Asp Arg Asp Ile Ser Asp Glu Thr 
115 120 125 
Leu Asp Lys Val Arg Gin Gin Ile Ile Asn Gin Glu Tyr Thr Lys Phe 
130 135 140 
Ser Phe Ile Ser Leu Gly Leu Asn Asp Asn Ser Ile Asn Glu Ser Val 
145 150 155 160 
US 10,633,643 B2 
25 26 
- continued 
Pro Val Ile Val Lys Thr Arg Val Pro Thr Thr Phe Asp Tyr Gly Val 
165 170 175 
Leu Asn Asp Lys Glu Thr Val Ser Leu Leu Leu Asn Gin Gly Phe Ser 
180 185 190 
Ile Ile Pro Glu Ser Ala Ile Ile Thr Thr Ile Lys Gly Lys Asp Tyr 
195 200 205 
Ile Leu Ile Glu Gly Ser Leu Ser Gin Glu Leu Asp Phe Tyr Asn Lys 
210 215 220 
Gly Ser Glu Ala Trp Gly Ala Glu Asn Tyr Gly Asp Tyr Ile Ser Lys 
225 230 235 240 
Leu Ser His Glu Gin Leu Gly Ala Leu Glu Gly Tyr Leu His Ser Asp 
245 250 255 
Tyr Lys Ala Ile Asn Ser Tyr Leu Arg Asn Asn Arg Val Pro Asn Asn 
260 265 270 
Asp Glu Leu Asn Lys Lys Ile Glu Leu Ile Ser Ser Ala Leu Ser Val 
275 280 285 
Lys Pro Ile Pro Gin Thr Leu Ile Ala Tyr Arg Arg Val Asp Gly Ile 
290 295 300 
Pro Phe Asp Leu Pro Ser Asp Phe Ser Phe Asp Lys Lys Glu Asn Gly 
305 310 315 320 
Glu Ile Ile Ala Asp Lys Gin Lys Leu Asn Glu Phe Ile Asp Lys Trp 
325 330 335 
Thr Gly Lys Glu Ile Glu Asn Leu Ser Phe Ser Ser Thr Ser Leu Lys 
340 345 350 
Ser Thr Pro Ser Ser Phe Ser Lys Ser Arg Phe Ile Phe Arg Leu Arg 
355 360 365 
Leu Ser Glu Gly Ala Ile Gly Ala Phe Ile Tyr Gly Phe Ser Gly Phe 
370 375 380 
Gin Asp Glu Gin Glu Ile Leu Leu Asn Lys Asn Ser Thr Phe Lys Ile 
385 390 395 400 
Phe Arg Ile Thr Pro Ile Thr Ser Ile Ile Asn Arg Val Thr Lys Met 
405 410 415 
Thr Gln Val Val Ile Asp Ala Glu Gly Ile Gin Asn Lys Glu Ile 
420 425 430 
< 210 > SEQ ID NO 4 
< 211 > LENGTH : 812 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Clostridium botulinum 
< 400 > SEQUENCE : 4 
Met Leu Val Ser Lys Phe Glu Asn Ser Val Lys Asn Ser Asn Lys Asn 
1 5 10 15 
Tyr Phe Thr Ile Asn Gly Leu Met Gly Tyr Tyr Phe Glu Asn Asp Phe 
20 25 30 
Phe Asn Leu Asn Ile Ile Ser Pro Thr Leu Asp Gly Asn Leu Thr Phe 
35 40 45 
Ser Lys Glu Asp Ile Asn Ser Ile Leu Gly Asn Lys Ile Ile Lys Ser 
50 55 60 
Ala Arg Trp Ile Gly Leu Ile Lys Pro Ser Ile Thr Gly Glu Tyr Ile 
65 70 75 80 
Leu Ser Thr Asn Ser Pro Asn Cys Arg Val Glu Leu Asn Gly Glu Ile 
85 90 95 
Phe Asn Leu Ser Leu Asn Thr Ser Asn Thr Val Asn Leu Ile Gin Gly 
100 105 110 
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Asn Val Tyr Asp Ile Arg Ile Glu Gln Leu Met Ser Glu Asn Gin Leu 
115 120 125 
Leu Lys Asn Tyr Glu Gly Ile Lys Leu Tyr Trp Glu Thr Ser Asp Ile 
130 135 140 
Ile Lys Glu Ile Ile Pro Ser Glu Val Leu Leu Lys Pro Asn Tyr Ser 
145 150 155 160 
Asn Thr Asn Glu Lys Ser Lys Phe Ile Pro Asn Asn Thr Leu Phe Ser 
165 170 175 
Asn Ala Lys Leu Lys Ala Asn Ala Asn Arg Asp Thr Asp Arg Asp Gly 
180 185 190 
Ile Pro Asp Glu Trp Glu Ile Asn Gly Tyr Thr Val Met Asn Gln Lys 
195 200 205 
Ala Val Ala Trp Asp Asp Lys Phe Ala Ala Asn Gly Tyr Lys Lys Tyr 
210 215 220 
Val Ser Asn Pro Phe Lys Pro Cys Thr Ala Asn Asp Pro Tyr Thr Asp 
225 230 235 240 
Phe Glu Lys Val Ser Gly Gin Ile Asp Pro Ser Val Ser Met Val Ala 
245 250 255 
Arg Asp Pro Met Ile Ser Ala Tyr Pro Ile Val Gly Val Gin Met Glu 
260 265 270 
Arg Leu Val Val Ser Lys Ser Glu Thr Ile Thr Gly Asp Ser Thr Lys 
275 280 285 
Ser Met Ser Lys Ser Thr Ser His Ser Ser Thr Asn Ile Asn Thr Val 
290 295 300 
Gly Ala Glu Val Ser Gly Ser Leu Gin Leu Ala Gly Gly Ile Phe Pro 
305 310 315 320 
Val Phe Ser Met Ser Ala Ser Ala Asn Tyr Ser His Thr Trp Gln Asn 
325 330 335 
Thr Ser Thr Val Asp Asp Thr Thr Gly Glu Ser Phe Ser Gin Gly Leu 
340 345 350 
Ser Ile Asn Thr Ala Glu Ser Ala Tyr Ile Asn Pro Asn Ile Arg Tyr 
355 360 365 
Tyr Asn Thr Gly Thr Ala Pro Val Tyr Asn Val Thr Pro Thr Thr Thr 
370 375 380 
Ile Val Ile Asp Lys Gin Ser Val Ala Thr Ile Lys Gly Gin Glu Ser 
385 390 395 400 
Leu Ile Gly Asp Tyr Leu Asn Pro Gly Gly Thr Tyr Pro Ile Ile Gly 
405 410 415 
Glu Pro Pro Met Ala Leu Asn Thr Met Asp Gin Phe Ser Ser Arg Leu 
420 425 430 
Ile Pro Ile Asn Tyr Asn Gin Leu Lys Ser Ile Asp Asn Gly Gly Thr 
435 440 445 
Val Met Leu Ser Thr Ser Gin Phe Thr Gly Asn Phe Ala Lys Tyr Asn 
450 455 460 
Ser Asn Gly Asn Leu Val Thr Asp Gly Asn Asn Trp Gly Pro Tyr Leu 
475 480 465 470 
Gly Thr Ile Lys Ser Thr Thr Ala Ser Leu Thr Leu Ser Leu Pro Asp 
485 490 495 
Gin Thr Thr Gin Val Ala Val Val Ala Pro Asn Phe Ser Asp Pro Glu 
500 505 510 
Asp Lys Thr Pro Arg Leu Thr Leu Glu Gln Ala Leu Val Lys Ala Phe 
515 520 525 
US 10,633,643 B2 
29 30 
- continued 
Arg Leu Glu Lys Lys Asn Gly Lys Phe Tyr Phe His Gly Met Glu Ile 
530 535 540 
Ser Ala Asn Gln Lys Ile Gin Val Phe Leu Asp Arg Asn Thr Asn Val 
545 550 555 560 
Asp Phe Glu Asn Gin Leu Lys Asn Thr Ala Asn Lys Asp Ile Met Asn 
565 570 575 
Cys Ile Ile Lys Arg Asn Met Asn Ile Leu Val Lys Val Ile Thr Gly 
580 585 590 
Ser Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu 
595 600 605 
Pro Glu Pro Glu Pro Gly Ser Thr Asn Val Val Lys Asp Tyr Trp Gly 
610 615 620 
Asn Asp Leu Arg Tyr Asn Lys Glu Tyr Tyr Met Val Asn Ile Asp Tyr 
625 630 635 640 
Leu Asn Arg Tyr Met Tyr Ala Asn Ser Arg Gin Ile Val Phe Asn Thr 
645 650 655 
Arg Arg Asn Asn Asn Asp Phe Asn Glu Gly Tyr Lys Ile Ile Ile Lys 
660 665 670 
Arg Ile Arg Gly Asn Thr Asn Asp Thr Arg Val Arg Gly Gly Asp Ile 
675 680 685 
Leu Tyr Phe Asp Met Thr Ile Asn Asn Lys Ala Tyr Asn Leu Phe Met 
690 695 700 
Lys Asn Glu Thr Met Tyr Ala Asp Asn His Ser Thr Glu Asp Ile Tyr 
705 710 715 720 
Ala Ile Gly Leu Arg Glu Gin Thr Lys Asp Ile Asn Asp Asn Ile Ile 
725 730 735 
Phe Gln Ile Gin Pro Met Asn Asn Thr Tyr Tyr Tyr Ala Ser Gln Ile 
740 745 750 
Phe Lys Ser Asn Phe Asn Gly Glu Asn Ile Ser Gly Ile Cys Ser Ile 
755 760 765 
Gly Thr Tyr Arg Phe Arg Leu Gly Gly Asp Trp Tyr Arg His Asn Tyr 
770 775 780 
Leu Val Pro Thr Val Lys Gin Gly Asn Tyr Ala Ser Leu Leu Glu Ser 
785 790 795 800 
Thr Ser Thr His Trp Gly Phe Val Pro Val Ser Glu 
805 810 
< 210 > SEQ ID NO 5 
< 211 > LENGTH : 24 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic 
< 400 > SEQUENCE : 5 
Gly Ser Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro 
1 5 10 15 
Glu Pro Glu Pro Glu Pro Gly Ser 
20 
< 210 > SEQ ID NO 6 
< 211 > LENGTH : 225 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Clostridium botulinum 
< 400 > SEQUENCE : 6 
Met Pro Ile Ile Lys Glu Pro Ile Asp Phe Ile Asn Lys Pro Glu Ser 
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1 5 10 15 
Glu Ala Lys Glu Trp Gly Lys Glu Glu Glu Lys Arg Trp Phe Thr Lys 
20 25 30 
Leu Asn Asn Leu Glu Glu Val Ala Val Asn Gin Leu Lys Asn Lys Glu 
35 40 45 
Tyr Lys Thr Lys Ile Asp Asn Phe Ser Thr Asp Ile Leu Phe Ser Ser 
50 55 60 
Leu Thr Ala Ile Glu Ile Met Lys Glu Asp Glu Asn Gin Asn Leu Phe 
65 70 75 80 
Asp Val Glu Arg Ile Arg Glu Ala Leu Leu Lys Asn Thr Leu Asp Arg 
85 90 95 
Asp Ala Ile Gly Tyr Val Asn Phe Thr Pro Lys Glu Leu Gly Ile Asn 
100 105 110 
Phe Ser Ile Arg Asp Val Glu Leu Asp Arg Asp Ile Ser Asp Glu Thr 
115 120 125 
Leu Asp Lys Val Arg Gin Gin Ile Ile Asn Gin Glu Tyr Thr Lys Phe 
130 135 140 
Ser Phe Ile Ser Leu Gly Leu Asn Asp Asn Ser Ile Asn Glu Ser Val 
145 150 155 160 
Pro Val Ile Val Lys Thr Arg Val Pro Thr Thr Phe Asp Tyr Gly Val 
165 170 175 
Leu Asn Asp Lys Glu Thr Val Ser Leu Leu Leu Asn Gin Gly Phe Ser 
180 185 190 
Ile Ile Pro Glu Ser Ala Ile Ile Thr Thr Ile Lys Gly Lys Asp Tyr 
195 200 205 
Ile Leu Ile Glu Gly Ser Leu Ser Gin Glu Leu Asp Phe Tyr Asn Lys 
210 215 220 
Gly 
225 
< 210 > SEQ ID NO 7 
< 211 > LENGTH : 21 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic 
< 400 > SEQUENCE : 7 
cgcggatcca tgctggtctc c 21 
< 210 > SEQ ID NO 8 
< 211 > LENGTH : 53 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : synthetic 
< 400 > SEQUENCE : 8 
ccggctctgg ttccggttca gaaccggtga tcactttgac cagaatattc atg 53 
< 210 > SEQ ID NO 9 
< 211 > LENGTH : 53 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : synthetic 
< 400 > SEQUENCE : 9 
ccagaaccag agccagaacc aggttctacc aacgttgtca aagactattg ggg 53 
US 10,633,643 B2 
33 34 
- continued 
< 210 > SEQ ID NO 10 
< 211 > LENGTH : 27 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : synthetic 
< 400 > SEQUENCE : 10 
cgggaattct tattctgaaa ccgggac 27 
< 210 > SEQ ID NO 11 
< 211 > LENGTH : 58 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : synthetic 
< 400 > SEQUENCE : 11 
aaccggaacc agagccggaa ccggaaccgg aaccggagcc agaaccagag ccagaacc 58 
< 210 > SEQ ID NO 12 
< 211 > LENGTH : 39 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : synthetic 
< 400 > SEQUENCE : 12 
cgcggatcca tgggcaccaa cgttgtcaaa gactattgg 39 
< 210 > SEQ ID NO 13 
< 211 > LENGTH : 30 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : synthetic 
< 400 > SEQUENCE : 13 
cgggaattct taggtgatca ctttgaccag 30 
< 210 > SEQ ID NO 14 
< 211 > LENGTH : 52 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : synthetic 
< 400 > SEQUENCE : 14 
cgcggatcca tgccgattat taaagaaccg attgacttca tcaacaaacc gg 52 
55 
60 
What is claimed is : derived from a second AB type of toxin , said second 
1. A composition for delivering an agent to a target cell , AB type being different from the first AB type , wherein 
comprising the target cell binding unit binds to a neural cell , and 
a target cell binding unit , wherein the target cell binding unit and the pore - forming 
a pore - forming unit , unit are covalently linked through the rigid synthetic 
a rigid synthetic linker linking the target cell binding unit linker to form a polypeptide having at least 90 % sequence identity to the amino acid sequence of SEQ and the pore - forming unit , and ID NO : 4 . 
a payload unit comprising the agent , wherein said payload 2. The composition of claim 1 , wherein the pore - forming 
unit binds non - covalently to a pore formed by the unit is a polypeptide or a polypeptide oligomer derived from pore - forming unit upon activation and oligomerization the pore - forming unit of Clostridium botulinum toxin C2 . 
of the pore - forming unit ; 3. The composition of claim 1 , wherein the composition 
wherein the pore - forming unit is a polypeptide derived 65 delivers the agent to a neural cell . 
from a first AB type of non - neurotoxic binary toxin , 4. The composition of claim 1 , wherein the target cell 
and wherein the target cell binding unit is a polypeptide binding unit is a polypeptide or a polypeptide oligomer 
10 
15 
20 
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derived from the binding domain of the heavy chain of C. a rigid synthetic linker linking the target cell binding unit 
botulinum neurotoxin C1 ( C1 Hcc ) . and the pore - forming unit , and 
5. The composition of claim 1 , wherein the agent com a payload unit comprising the agent , wherein said payload 
prises at least one member selected from the group consist unit binds non - covalently to a pore formed by the 
ing of a therapeutic agent , a diagnostic agent , and combi - 5 pore - forming unit upon activation and oligomerization 
nations thereof . of the pore - forming unit ; wherein the pore - forming unit is a polypeptide derived 6. The composition of claim 1 , wherein the agent com from a first AB type of non - neurotoxic binary toxin , prises at least one member selected from the group consist and wherein the target cell binding unit is a polypeptide 
ing of a toxin , a cell cycle blocker , an apoptosis inducing derived from a second AB type of toxin , said second 
agent , an inhibitor of DNA replication , an inhibitor of RNA AB type being different from the first AB type , and 
synthesis , an inhibitor of protein synthesis , an enzyme , a wherein the target cell binding unit binds to a neural 
protein binding agent , an antibody , a neutralizing antibody , cell ; and 
a labeling agent , magnetic beads , and combinations thereof . wherein the rigid synthetic linker comprises a polypeptide 
7. The composition of claim 1 , wherein the agent com having at least 90 % sequence identity to the amino acid 
prises an ADP - ribosyltransferase . sequence set forth in SEQ ID NO : 5 . 
8. The composition of claim 1 , wherein the agent com 16. The composition of claim 1 , wherein the neural cell is 
prises C21 from Clostridium botulinum toxin C2 . a sensory neuron . 
9. The composition of claim 1 , wherein the agent com 17. A composition for delivering an agent to a target cell , 
prises a fluorescent agent . comprising 
10. The composition of claim 1 , wherein the target cell a target cell binding unit , 
binding unit comprises the binding domain of the heavy a pore - forming unit , 
chain of C. botulinum neurotoxin C1 ( C1 Hcc ) , wherein the a rigid synthetic linker linking the target cell binding unit 
pore - forming unit comprises the pore - forming domain of and the pore - forming unit , and 
Clostridium botulinum toxin C - 2 , and wherein the payload a payload unit comprising the agent , wherein said payload 
unit comprises C21 from Clostridium botulinum toxin C - 2 . unit binds non - covalently to a pore formed by the 
11. The composition of claim 1 , wherein the payload unit pore - forming unit upon activation and oligomerization 
comprises a polypeptide having at least 90 % sequence of the pore - forming unit ; 
identity to amino acid sequence of SEQ ID NO : 6 . wherein the pore - forming unit is a polypeptide derived 
12. A method of delivering an agent to a target cell , from a first AB type of non - neurotoxic binary toxin , 
comprising administering the composition of claim 1 to a and wherein the target cell binding unit is a polypeptide derived from a second AB type of toxin , said second 
13. The method of claim 12 , wherein the composition is AB type being different from the first AB type , wherein 
administered to a subject by injection , wherein the subject the target cell binding unit binds to a neural cell , and 
comprises the target cell . wherein the target cell binding unit comprises a polypep 
14. The method of claim 12 , wherein the target cell is a tide having at least 90 % sequence identity to the amino 
member selected from the group consisting of a cell of a acid sequence 230-426 of SEQ ID NO : 1 , wherein the 
brain tumor , a cell of a neuroblastoma , and a cell of a pore - forming unit comprises a polypeptide having at 
retinoblastoma , peripheral neuron ; motor neuron , sensory least 90 % sequence identity to the amino acid sequence 
neuron , and combination thereof . 1-591 of SEQ ID NO : 2 , and 
15. A composition for delivering an agent to a target cell , wherein the rigid synthetic linker comprises a polypeptide 
comprising having at least 90 % sequence identity to the amino acid 
a target cell binding unit , sequence set forth in SEQ ID NO : 5 . 
a pore - forming unit , 
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target cell . 
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